1 dated access item. Most recent: State exclusion lists keep moving, and programs rarely announce it (2026-03-20).
Access items cover who can actually receive a prescription, which is set state by state and programme by programme rather than nationally.
Why access developments matter here
Two licences have to line up for any shipment: the prescriber must hold one in your state, and the pharmacy must be registered to ship into it. Gaps are regulatory rather than clinical judgements about patients.
Service maps change without announcement, including after enrolment. Any published state list, ours included, is a starting point; the binding answer appears at checkout.
All access items
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.